Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
EGLT's Cash to Debt is ranked higher than
87% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. EGLT: No Debt )
EGLT' s 10-Year Cash to Debt Range
Min: 0.91   Max: No Debt
Current: No Debt

Equity to Asset 0.79
EGLT's Equity to Asset is ranked higher than
82% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. EGLT: 0.79 )
EGLT' s 10-Year Equity to Asset Range
Min: 0.79   Max: 0.85
Current: 0.79

0.79
0.85
Z-Score: 2.72
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -2957.51
EGLT's Operating margin (%) is ranked higher than
54% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. EGLT: -2957.51 )
EGLT' s 10-Year Operating margin (%) Range
Min: -943.77   Max: -440.97
Current: -2957.51

-943.77
-440.97
Net-margin (%) -4025.64
EGLT's Net-margin (%) is ranked higher than
52% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. EGLT: -4025.64 )
EGLT' s 10-Year Net-margin (%) Range
Min: -1031.47   Max: -449.46
Current: -4025.64

-1031.47
-449.46
ROE (%) -129.54
EGLT's ROE (%) is ranked higher than
56% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. EGLT: -129.54 )
EGLT' s 10-Year ROE (%) Range
Min: 0   Max: 0
Current: -129.54

ROA (%) -85.56
EGLT's ROA (%) is ranked higher than
55% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. EGLT: -85.56 )
EGLT' s 10-Year ROA (%) Range
Min: -155.7   Max: -140.37
Current: -85.56

-155.7
-140.37
ROC (Joel Greenblatt) (%) -1466.27
EGLT's ROC (Joel Greenblatt) (%) is ranked higher than
65% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. EGLT: -1466.27 )
EGLT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1137.7   Max: -674.1
Current: -1466.27

-1137.7
-674.1
» EGLT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

EGLT Guru Trades in

EGLT Guru Trades in

EGLT Guru Trades in

Q1 2014

EGLT Guru Trades in Q1 2014

Steven Cohen 31,594 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with EGLT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.10
EGLT's P/B is ranked higher than
88% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. EGLT: 2.10 )
EGLT' s 10-Year P/B Range
Min: 1.41   Max: 4.44
Current: 2.1

1.41
4.44
P/S 79.30
EGLT's P/S is ranked higher than
70% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 32.74 vs. EGLT: 79.30 )
EGLT' s 10-Year P/S Range
Min: 53   Max: 603
Current: 79.3

53
603
PFCF 2.00
EGLT's PFCF is ranked higher than
100% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. EGLT: 2.00 )
EGLT' s 10-Year PFCF Range
Min: 1.33   Max: 10.11
Current: 2

1.33
10.11
EV-to-EBIT -1.73
EGLT's EV-to-EBIT is ranked lower than
51% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. EGLT: -1.73 )
EGLT' s 10-Year EV-to-EBIT Range
Min: -6.8   Max: -0.3
Current: -1.73

-6.8
-0.3
Current Ratio 12.74
EGLT's Current Ratio is ranked higher than
91% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. EGLT: 12.74 )
EGLT' s 10-Year Current Ratio Range
Min: 0.59   Max: 29.19
Current: 12.74

0.59
29.19
Quick Ratio 12.74
EGLT's Quick Ratio is ranked higher than
91% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. EGLT: 12.74 )
EGLT' s 10-Year Quick Ratio Range
Min: 0.59   Max: 29.19
Current: 12.74

0.59
29.19

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.39
EGLT's Price/Net Cash is ranked higher than
95% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 64.50 vs. EGLT: 2.39 )
EGLT' s 10-Year Price/Net Cash Range
Min: 2.31   Max: 4.07
Current: 2.39

2.31
4.07
Price/Net Current Asset Value 2.37
EGLT's Price/Net Current Asset Value is ranked higher than
95% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 34.97 vs. EGLT: 2.37 )
EGLT' s 10-Year Price/Net Current Asset Value Range
Min: 2.29   Max: 4.05
Current: 2.37

2.29
4.05
Price/Tangible Book 2.11
EGLT's Price/Tangible Book is ranked higher than
92% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. EGLT: 2.11 )
EGLT' s 10-Year Price/Tangible Book Range
Min: 2.04   Max: 3.69
Current: 2.11

2.04
3.69
Price/Median PS Value 0.39
EGLT's Price/Median PS Value is ranked higher than
96% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. EGLT: 0.39 )
EGLT' s 10-Year Price/Median PS Value Range
Min: 0.38   Max: 2.31
Current: 0.39

0.38
2.31
Earnings Yield (Greenblatt) -57.80
EGLT's Earnings Yield (Greenblatt) is ranked higher than
50% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. EGLT: -57.80 )
EGLT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -57.8

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
» More Articles for EGLT

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Nasdaq stocks posting largest percentage decreases Nov 26 2014
EGALET CORP Financials Nov 21 2014
EGALET CORP Files SEC form 10-Q, Quarterly Report Nov 14 2014
EGALET CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 12 2014
Egalet Reports Third Quarter 2014 Financial Results and Provides Business Update Nov 12 2014
Egalet Reports Third Quarter 2014 Financial Results and Provides Business Update Nov 12 2014
Egalet to Present at the Stifel 2014 Healthcare Conference on November 18 Nov 05 2014
Egalet to Present at the Stifel 2014 Healthcare Conference on November 18 Nov 05 2014
Egalet to Host Conference Call and Webcast to Discuss Third Quarter Financial Results on November... Oct 29 2014
Egalet to Host Conference Call and Webcast to Discuss Third Quarter Financial Results on November... Oct 29 2014
2 Oversold Stocks Under $10 Ready to Bounce Higher Oct 17 2014
Egalet (EGLT) Shows Strength: Stock Moves 7.1% Higher Oct 13 2014
Midday movers: Hasbro, KB Home, Transocean & more Sep 24 2014
UPDATE: Stifel Reiterates, Lowers Price Target On Egalet Corp As Filing Delay Is Likely Sep 24 2014
EGALET CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 24 2014
Egalet Announces Update on Clinical Development Plan for Abuse-Deterrent Morphine Egalet-001 Sep 23 2014
Egalet Announces Issuance of U.S. Patents Covering Guardian(TM) Technology and Product Candidates Sep 11 2014
EGALET CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 04 2014
Egalet to Present Data from Abuse-Deterrence Studies at PAINWeek 2014 in Las Vegas Sep 04 2014
Biotech Analyst Optimism: Price Targets Post-IPO Aug 29 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK